Glipizide Extended Release Tablets

This product is a glipizide controlled-release tablet designed according to a special gastrointestinal therapeutic system (GITS). It is wrapped by a semipermeable membrane and contains glipizide and a non-pharmacologically active ingredient that can absorb water. The tablet swells after absorbing water, and glipizide is released from the small holes punched by the laser. Two hours after oral administration, the active ingredient (glipizide) begins to be released stably, which can be maintained for about 8 hours. The release rate gradually decreases, and the release is completed about 16 hours after taking the medicine. The elimination half-life of glipizide gradually absorbed into the blood in the intestine is about 2.5 to 4 hours. The blood drug concentration can be maintained within 24 hours after taking the medicine. After taking 5 mg orally once, the average blood drug concentration in 24 hours can reach more than 50ng/ml. Taking the medicine once a day can control blood sugar throughout the day. After taking the medicine for 5 days, the blood drug concentration reaches a steady state, and it takes 6 to 7 days for elderly patients to reach a steady state.

Glipizide

This product is a white film-coated tablet, which reveals a double-layer core of reddish brown and light red after removing the coating.

It is suitable for patients with mild to moderate type 2 diabetes who have not achieved satisfactory results with diet control and physical exercise for 2 to 3 months. The pancreatic beta cells of such diabetic patients must have a certain insulin secretion function, and have no acute complications (such as infection trauma, ketoacidosis, hyperosmolar coma, etc.), no pregnancy, and no serious chronic complications.

Oral: Take the medicine once a day. Start with 5 mg a day, taken at breakfast (or at other convenient times). Adjust the dose based on weekly blood sugar levels or bimonthly glycated hemoglobin levels. Most patients can take 10 mg a day, some patients need to take 15 mg, and the maximum daily dose is 20 mg.

This product has fewer adverse reactions. 1. Endocrine and metabolic system: This product belongs to the sulfonylurea drug, and the adverse reaction of this type of drug is mainly hypoglycemia. 2. Digestive system: 1. Digestive tract reactions such as nausea, vomiting, upper abdominal burning sensation, loss of appetite, diarrhea, and metallic taste in the mouth may occur. They are generally not serious and are related to large doses. Sometimes it can increase appetite and cause weight gain. 2. Liver damage: Jaundice and abnormal liver function are rare. 3. Blood system: Adverse reactions of the blood system are rare, including leukopenia, agranulocytosis, anemia, and thrombocytopenia. 4. Allergic reactions: such as rash, and occasionally exfoliative dermatitis occurs.

1. Patients allergic to sulfonamides. 2. Patients with type 1 diabetes who have been diagnosed. 3. Patients with type 2 diabetes accompanied by stressful conditions such as ketoacidosis, coma, severe burns, infection, trauma, and major surgery. 4. Patients with impaired liver and kidney function. 5. Patients with leukopenia.

Precautions for children: The safety and effectiveness of glipizide for children have not been established, so it is not recommended for children. Precautions for pregnancy and lactation: This product is contraindicated for pregnant women. Although it is not known whether glipizide is excreted through human milk, it is known that some sulfonylurea drugs can be excreted through breast milk. Because of the possibility of causing hypoglycemia in breastfeeding infants, the importance of the drug to the mother should be considered to decide whether to stop breastfeeding or stop taking hypoglycemic drugs. If the drug is discontinued and diet therapy alone is not enough to control blood sugar, insulin therapy should be considered. Precautions for the elderly: There is no significant difference in the pharmacokinetics of glipizide in elderly diabetic subjects after a single dose compared with young healthy subjects, but the higher sensitivity of some patients cannot be ruled out. After multiple doses, it takes about 1 to 2 days longer for the elderly to reach steady-state blood drug concentrations.

1. Combination with the following drugs may increase the incidence of hypoglycemia. (1) Drugs that inhibit the excretion of sulfonylureas (SU) in urine, such as probenecid and allopurinol for the treatment of gout. (2) Drugs that slow down the metabolism of SU, such as alcohol, H2 receptor blockers (cimetidine, ranitidine), chloramphenicol, antifungal drug miconazole, and anticoagulants. Sulfonylureas and alcohol taken together can cause abdominal pain, nausea, vomiting, headache, and facial flushing (especially when used with chlorpropamide). When used in combination with coumarin anticoagulants, the plasma concentrations of both drugs increase at first, and then decrease. Therefore, the dosage of the two drugs should be adjusted according to the situation. (3) Drugs that promote the separation of SU from bound plasma albumin, such as salicylates and lipid-lowering drugs fibrates. (4) Drugs that have the effect of causing hypoglycemia: alcohol, salicylates, guanethidine, monoamine oxidase inhibitors, and quinidine. (5) Use other hypoglycemic drugs in combination: insulin, metformin, acarbose, insulin sensitizers. (6) Beta-adrenergic receptor blockers can interfere with the body's blood sugar-raising response during hypoglycemia, hinder liver glycolysis, and at the same time mask the warning symptoms of hypoglycemia. 2 The following drugs can increase blood sugar when used with SU, and the dose of SU may need to be increased: glucocorticoids, estrogen, thiazide diuretics, phenytoin sodium, rifampicin. Beta-adrenergic receptor blockers can antagonize the insulin-secreting effect of SU, so they can also cause hyperglycemia.

Keep away from light and store in sealed container.

5mg

24 months

Changzhou Siyao Pharmaceuticals Co., Ltd.

• Founded in:

  1996-03-25

• Address:

  Meilongba, southern suburb of Changzhou, Jiangsu Province

• Tax NO.:

  91320400608126461P

• Registered Funds:

  $7.08 million

• Website:

  Log in to view

• Email:

  Log in to view